il-6

IL-6 (Interleukin-6)

A pleiotropic secreted cytokine that occupies a central node in the biology of aging: acutely beneficial (tissue repair, exercise-induced metabolic signaling), chronically harmful when basally elevated as part of SASP and inflammaging. Druggability-tier 1 via FDA-approved receptor-blocking antibodies in clinical use. The IL-6 paradox — acute anti-inflammatory myokine vs. chronic pro-inflammatory driver — is one of the clearest illustrations of context-dependence in aging biology.

Identity

• UniProt: P05231 (IL6_HUMAN), manually curated Swiss-Prot entry
• NCBI Gene: 3569 · HGNC symbol: IL6 · HGNC ID: 6018
• Ensembl: ENSG00000136244
• GenAge (HAGR) entry: 144 — classified “indirect or inconclusive” for human longevity; IL-6 polymorphisms correlate with cardiovascular disease risk but not with human longevity in population studies
• Chromosomal location: 7p15.3
• Protein length: 212 aa (pre-pro-protein); signal peptide aa 1–29; mature secreted form aa 30–212 (~20 kDa; heavily glycosylated, apparent MW 22–27 kDa)
• Mouse ortholog: Il6 (one-to-one; high functional conservation)

Structure

IL-6 belongs to the IL-6 family of cytokines (also called gp130 cytokines), all sharing a four-helix-bundle topology. The family includes IL-6, IL-11, IL-27, LIF, OSM, CNTF, CT-1, and CLC. Common feature: signaling through the shared receptor subunit gp130 (encoded by IL6ST).

Key structural features:

• Four α-helical bundle (helix A–D) — defines the IL-6 superfamily fold
• Site I, II, III binding surfaces — mediate sequential receptor assembly (IL-6R binding at site I; gp130 recruitment at sites II/III)
• Disulfide bonds: Cys72–Cys78 and Cys101–Cys111 — required for structural integrity
• Glycosylation: N-linked (Asn73) + O-linked — accounts for variability in apparent molecular weight and modulates receptor affinity and half-life

Signaling modes

IL-6 can engage cells via three structurally and functionally distinct signaling modes. The distinction between classical and trans-signaling is clinically actionable — selective trans-signaling inhibition is a therapeutic strategy (olamkicept) ^{1 2}.

1. Classical signaling (membrane IL-6R)

Cells capable: hepatocytes, leukocytes, and a small number of cell types that express membrane-bound IL-6R (IL6RA, CD126)

Assembly sequence:

1. IL-6 binds membrane IL-6R (IL6RA)
2. IL-6:IL6RA complex recruits two gp130 (IL6ST) subunits → hexameric complex
3. JAK1/JAK2 (associated with gp130) trans-phosphorylate → STAT3 activation
4. Downstream: STAT3 → acute-phase proteins; PI3K→AKT; MAPK/ERK

Biological character: Predominantly tissue-protective, regenerative, anti-inflammatory. Mediates acute-phase response in liver (fibrinogen, CRP, hepcidin, serum amyloid A); supports hepatocyte proliferation after partial hepatectomy; promotes differentiation of B cells into antibody-secreting plasma cells; protective neurotropic effects in neural tissue.

2. Trans-signaling (soluble IL-6R)

Cells capable: essentially all cells, because gp130 is ubiquitously expressed

Assembly sequence:

1. Soluble IL-6R (sIL-6R) — shed from the membrane surface of neutrophils, monocytes, and hepatocytes primarily by ADAM17 metalloprotease cleavage (ADAM10 plays a secondary role in apoptosis-induced shedding; ADAM17 is the dominant sheddase in inflammatory contexts) — circulates in plasma at approximately 75 ng/mL in healthy adults; the endogenous soluble decoy sgp130 circulates at ~250–400 ng/mL ¹
2. IL-6 binds sIL-6R in the circulation
3. The IL-6:sIL-6R complex engages gp130 on any cell (even those lacking membrane IL-6R)
4. Same intracellular signaling cascade as classical (JAK/STAT3/MAPK/PI3K)

Biological character: Predominantly pro-inflammatory. Responsible for most of IL-6’s pathological effects: endothelial activation, chemoattractant production, T-cell survival, inhibition of regulatory T-cell differentiation, and promotion of pathogenic effector T-cell populations ¹. The rise of sIL-6R with age amplifies trans-signaling capacity independently of IL-6 concentration changes.

Selective blockade: Soluble gp130 (sgp130) is the endogenous trans-signaling inhibitor — it binds IL-6:sIL-6R complexes but not membrane IL-6R complexes. The engineered Fc-fusion olamkicept (sgp130Fc) selectively inhibits trans-signaling; in a Phase 2a IBD trial, 44% clinical response rate ². This mechanism spares classical signaling’s regenerative and hepatoprotective functions — a potentially important advantage over non-selective anti-IL-6R blockade for aging indications.

3. Trans-presentation (newest mode)

Description: Membrane IL-6Rα expressed on CD11b+Sirpα+CD103⁻SiglecH⁻ dendritic cells (the cDC2 subset) presents IL-6 to gp130 on adjacent T cells via direct cell-cell contact during cognate antigen presentation (termed “IL-6 cluster signaling” by Heink et al.). IL-6 is loaded intracellularly onto IL-6Rα within DCs before transport to the membrane interface; unlike trans-signaling, anti-IL-6 antibodies fail to block this mode ³.

Biological relevance: Required for priming pathogenic TH17 cells; distinct from the ambient IL-6 that suppresses regulatory T-cell differentiation. May be relevant to autoimmune-inflammatory amplification in aging tissues but direct aging-context evidence is limited. needs-human-replication

Downstream signaling

Following gp130 activation (all three signaling modes):

Branch	Key mediators	Outcomes
JAK/STAT3	JAK1, JAK2, STAT3	Acute-phase proteins; gene-expression programs; cell survival
MAPK/ERK	RAS → RAF → MEK → ERK	Cell proliferation, differentiation
PI3K/AKT	PI3K → AKT → mTOR	Metabolic effects, cell survival, protein synthesis

Negative regulators: SOCS1/SOCS3 (JAK inhibitors induced by STAT3 as negative feedback), SHP2 (tyrosine phosphatase), sgp130 (endogenous trans-signaling decoy).

Expression sources in aging

• Macrophages / monocytes: primary producers in systemic inflammation; classical NLRP3 inflammasome-IL-1β axis induces IL-6 via NF-κB
• Senescent cells (SASP): a major source of basally elevated IL-6 in aged tissues — SASP-derived IL-6 drives paracrine senescence spread and tissue dysfunction ⁴
• Adipose tissue: adipocytes and adipose-resident macrophages; fat mass increases with age and proportionally increases adipose IL-6 output
• Fibroblasts and endothelial cells: respond to and amplify inflammatory signals
• Skeletal muscle (acute exercise only): IL-6 is the canonical exercise-induced myokine — released from contracting muscle fibers via glycogen-depletion signaling, peaking 5–10× above baseline during endurance exercise and returning to baseline within hours ⁵. This acute myokine IL-6 is mechanistically distinct from basally elevated IL-6: it drives fatty-acid oxidation, glucose uptake, and anti-inflammatory IL-1Ra / IL-10 production — net anti-inflammatory.

IL-6 and aging: the inflammaging axis

Chronic low-grade elevation of IL-6 is among the most consistently replicated biomarkers of aging across population cohorts ⁴. Serum IL-6 rises approximately 2–4-fold from early adulthood to age 80 in healthy individuals, and predicts all-cause mortality, disability, and frailty independently of chronological age. See il-6-biomarker for clinical-interpretation context.

Mechanistic contributions to age-related pathology:

• SASP amplification — senescent cells secrete IL-6, which can induce paracrine senescence in neighboring cells via gp130 signaling; self-amplifying loop
• Muscle wasting (sarcopenia) — trans-signaling-mediated inhibition of satellite cell activation and IGF-1 signaling; IL-6 knockout mice show enhanced regeneration post-injury
• Immunosenescence — chronic IL-6 trans-signaling shifts T-cell differentiation away from naive/regulatory toward effector/exhausted phenotypes
• Metabolic dysregulation — sustained IL-6 trans-signaling drives insulin resistance in adipose and liver; distinct from acute-exercise myokine effect
• Vascular disease — IL-6 trans-signaling promotes endothelial activation, VCAM-1 upregulation, and atherosclerotic plaque destabilization

Mendelian randomization evidence

The IL-6R MR Collaboration (2012, Lancet) used the IL6R rs7529229 SNP as the lead analytic instrument — a tagging SNP in strong LD (r²=0.92) with the functional non-synonymous variant rs8192284 (p.Asp358Ala, also annotated as rs2228145). The Asp358Ala substitution increases proteolytic shedding of membrane IL-6R by ADAM17, raising circulating sIL-6R and paradoxically attenuating downstream IL-6 inflammatory signaling. Across 40 studies including up to 133,449 individuals for biomarker analyses, and 34 studies with 25,458 CHD cases / 100,740 controls for the primary endpoint, each additional minor allele was associated with OR 0.95 (95% CI 0.93–0.97), p=1.53×10⁻⁵ for fatal or non-fatal CHD — a modest per-allele risk reduction consistent with lifelong partial moderation of IL-6R signaling ⁶. This MR evidence supports a causal role of the IL-6/IL-6R axis in coronary heart disease and validates IL-6R as a cardiovascular drug target.

Dimension	Status	Notes
Pathway conserved in humans?	yes	gp130/JAK/STAT3 highly conserved; human MR evidence available
Phenotype conserved in humans?	yes	IL-6 elevation predicts mortality and frailty in multiple human cohorts
Replicated in humans?	yes (cardiovascular) / partial (aging per se)	Strong for CVD via MR; aging-specific RCT data limited

The IL-6 paradox: context is everything

The same cytokine is:

• Pro-aging (chronic basal elevation): SASP component, senescence amplifier, insulin-resistance driver, muscle-catabolism promoter, immune-function disruptor
• Anti-aging (acute exercise-induced): promotes fat oxidation, insulin sensitivity, anti-inflammatory cytokine induction (IL-1Ra, IL-10), liver glucose metabolism, and exercise-adaptation

Mechanistically, the paradox partially resolves by signaling mode: acute muscle-derived IL-6 operates mainly via classical signaling on hepatocytes (IL-6R+) and muscles; chronic basal IL-6 accumulates sIL-6R and operates via trans-signaling on all tissues. Amplitude and duration also matter — transient high-amplitude spikes (exercise) vs. continuous low-amplitude elevation (SASP/inflammaging).

Therapeutic implication: global IL-6 blockade (tocilizumab/siltuximab) abolishes both the harmful chronic and the beneficial acute signals; selective trans-signaling inhibition (olamkicept) may spare the protective classical arm. Relevant for aging-indication drug development.

Pharmacology

FDA-approved agents targeting IL-6 axis

Agent	Target	Indication	Year approved
Tocilizumab (Actemra)	IL-6R (anti-IL-6Rα mAb)	RA, GCA, CRS, COVID-19	2010 (RA) / 2022 (COVID-19)
Siltuximab (Sylvant)	IL-6 (anti-IL-6 mAb)	Multicentric Castleman disease	2014
Sarilumab (Kevzara)	IL-6R (anti-IL-6Rα mAb)	RA	2017
Satralizumab (Enspryng)	IL-6R	Neuromyelitis optica spectrum disorder	2020

Aging-context tier-1 rationale: Multiple FDA-approved agents block the IL-6/IL-6R/gp130 axis. Tocilizumab is being investigated in aging contexts: geroscience-hypothesis trials targeting inflammaging (e.g., Taming Aging with Metformin (TAME) comparators, frailty pilot studies). Tier-1 designates that a clinical drug exists and is being explored in aging-relevant contexts, not that an aging-indication FDA approval exists.

Investigational aging-context agents

• Olamkicept (sgp130Fc): selective IL-6 trans-signaling inhibitor; Phase 2a IBD trial (Schreiber 2021: 44% clinical response) ²; potential advantage for aging use due to sparing of classical signaling’s regenerative functions. No aging-indication trial yet. needs-human-replication
• Anti-IL-6 senolytic combinations: not directly IL-6-targeted but senolytics (navitoclax, dasatinib + quercetin) reduce SASP-derived IL-6 as a downstream effect

Cross-links

• Biomarker page: il-6-biomarker — clinical-interpretation context, aging cohort data, assay considerations
• Process pages: sasp — IL-6 as a central SASP component
• Pathway pages: jak-stat-pathway — downstream JAK1/2/STAT3 signaling; nf-kb — upstream transcriptional induction of IL-6 in senescent cells and macrophages
• Hallmark pages: chronic-inflammation · altered-intercellular-communication · cellular-senescence

Limitations and gaps

• GTEx aging correlation absent: IL-6 is primarily regulated post-transcriptionally and at secretion level; bulk RNA-seq aging correlation is uninformative for this cytokine. Protein-level aging data is the relevant measure; see il-6-biomarker. needs-gtex-aging-correlation
• Trans-presentation in aging: Heink 2017 established the trans-presentation mode in TH17 priming, but its quantitative contribution to aging-specific inflammation relative to classical and trans-signaling modes is unknown. no-mechanism
• Selective trans-signaling inhibition in aging: No aging-indication trial of olamkicept or any selective trans-signaling inhibitor exists. The mechanistic rationale is strong; human evidence gap remains. needs-human-replication
• Causal direction of SASP-IL-6 loop: Whether IL-6 drives senescence accumulation (→ amplifies SASP) or only reflects it remains contested; interventional data (senolytics lowering IL-6) supports bidirectionality but causality requires further dissection. contradictory-evidence
• Dose-response for beneficial vs. harmful effects: Threshold between acute-beneficial and chronic-harmful IL-6 signaling not quantitatively defined in humans. dose-response-unclear

Footnotes

Footnotes

1. doi:10.7150/ijbs.4989 · Rose-John S · Int J Biol Sci 2012 · review · defines classical vs. trans-signaling distinction; sIL-6R steady-state plasma ~75 ng/mL; sgp130 ~250–400 ng/mL; ADAM17 primary sheddase; 970+ citations; locally downloaded PDF — verified against full text ↩ ↩² ↩³

2. doi:10.1053/j.gastro.2021.02.062 · Schreiber S et al. · Gastroenterology 2021 · Phase 2a open-label prospective trial (FUTURE) · olamkicept (sgp130Fc) in active IBD; n=16; 44% clinical response, 19% remission; confirmed STAT3 phosphorylation reduction; hybrid OA — full PDF not accessible via PMC (download failed); 44%/19% figures confirmed against PubMed abstract needs-full-pdf-verification ↩ ↩² ↩³

3. doi:10.1038/ni.3632 · Heink S, Korn T et al. · Nat Immunol 2017 Jan;18(1):74–85 · in-vivo (mouse) + in-vitro · establishes “IL-6 cluster signaling” / trans-presentation mode by CD11b+Sirpα+CD103⁻SiglecH⁻ DCs (cDC2 subset) using DC membrane-bound IL-6Rα to trans-present IL-6 to gp130 on adjacent T cells; required for pathogenic TH17 priming in EAE model; anti-IL-6 antibodies fail to block cluster signaling; locally downloaded PDF — verified against full text ↩

4. doi:10.1111/j.1749-6632.2000.tb06651.x · Franceschi C et al. · Ann NY Acad Sci 2000 · review · introduced the “inflamm-aging” concept linking chronic basal IL-6 elevation to age-related disease; >5000 citations; not locally downloaded ↩ ↩²

5. doi:10.1016/j.tips.2007.02.002 · Pedersen BK, Fischer CP · Trends Pharmacol Sci 2007 · review · exercise-induced IL-6 as anti-inflammatory myokine; not locally downloaded (status: not_oa) ↩

6. doi:10.1016/S0140-6736(12)60110-X · IL-6R MR Collaboration (Swerdlow D et al.) · Lancet 2012 · Mendelian randomization · 40 studies, up to 133,449 individuals for biomarker analyses; CHD endpoint: 25,458 cases, 100,740 controls across 34 studies; lead instrument rs7529229 (LD r²=0.92 with functional rs8192284/rs2228145 p.Asp358Ala); per-allele OR 0.95 (95% CI 0.93–0.97), p=1.53×10⁻⁵ for CHD; locally available PDF — verified against full text ↩